The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Real-world safety and healthcare resource utilization (HCRU) of lurbinectedin (lurbi) in patients (pts) with small cell lung cancer (SCLC): Jazz EMERGE 402 updated analysis.
 
Firas Benyamine Badin
Consulting or Advisory Role - Amgen; Bristol Myers Squibb Foundation; Guardant Health; Janssen; Jazz Pharmaceuticals; Lilly; Merck; Natera; Pfizer; Regeneron
Speakers' Bureau - Amgen; Bristol Myers Squibb Foundation; Guardant Health; Janssen; Jazz Pharmaceuticals; Lilly; Merck; Natera; Pfizer; Regeneron
Research Funding - Amgen; Bristol Myers Squibb Foundation; Guardant Health; Janssen; Jazz Pharmaceuticals; Lilly; Merck; Natera; Pfizer; Regeneron
 
Philip Edward Lammers
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo; Merck; Pfizer; Roche/Genentech; Sanofi; Teva
 
Mehul P. Patel
No Relationships to Disclose
 
Leonid Shunyakov
Consulting or Advisory Role - Agendia; Amgen; Astellas Amgen BioPharma; AstraZeneca; BeiGene; Bristol-Myers Squibb; Exelixis; Genentech; GlaxoSmithKline; Guardant Health; Janssen; Jazz Pharmaceuticals; JJ Innovative Medicine; Karyopharm Therapeutics; Merck; Mirati Therapeutics; MorphoSys; Pfizer; Regeneron; Roche; Sanofi; Seagen; TG Therapeutics
Research Funding - BeiGene; BeyondSpring Pharmaceuticals; Biodesix
Travel, Accommodations, Expenses - Amgen; Bristol Myers Squibb Foundation; Exelixis; Genentech; Janssen; Merck; Seagen
 
Dennis Slater
No Relationships to Disclose
 
Catherine Labbé
Consulting or Advisory Role - Amgen; AstraZeneca; Bristol-Myers Squibb; EMD Serono; Genzyme; Jazz Pharmaceuticals; LEO Pharma; Lilly; Merck; Novartis; Pfizer; Roche
 
Navit Naveh
Employment - Jazz Pharmaceuticals
Stock and Other Ownership Interests - Jazz Pharmaceuticals
 
Anne Boccuti
Employment - Jazz Pharmaceuticals
Stock and Other Ownership Interests - Jazz Pharmaceuticals
 
Raj Hanvesakul
Employment - Jazz Pharmaceuticals
Stock and Other Ownership Interests - Jazz Pharmaceuticals
 
Wenyan Li
Employment - Jazz Pharmaceuticals
Stock and Other Ownership Interests - Jazz Pharmaceuticals
 
Badri Rengarajan
Employment - Jazz Pharmaceuticals
Stock and Other Ownership Interests - Jazz Pharmaceuticals
 
Balazs Halmos
Consulting or Advisory Role - Apollomics; Arcus Biosciences; AstraZeneca; Bayer; BeiGene; Bristol-Myers Squibb; Daiichi Sankyo/Lilly; Genentech/Roche; Janssen Oncology; Lilly; Merck; merus; Novartis; Pfizer; Takeda; Turning Point Therapeutics; Veracyte
Research Funding - Abbvie (Inst); Advaxis (Inst); Amgen; AstraZeneca (Inst); Black Diamond Therapeutics (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo/Astra Zeneca (Inst); Elevation Oncology (Inst); Forward (Inst); GlaxoSmithKline (Inst); Janssen Oncology (Inst); Jazz Pharmaceuticals (Inst); Merck (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); Regeneron (Inst); Roche/Genentech (Inst); Takeda (Inst); Tesaro/GSK (Inst)